Abstract. Traumatic brain injury results in a profound decline in intracellular magnesium ion levels that may jeopardize critical cellular functions. We examined the consequences of preinjury magnesium deficiency and post-traumatic magnesium treatment on injury-induced cytoskeletal damage and cell death at 24 h after injury. Adult male rats were fed either a normal (n ϭ 24) or magnesium-deficient diet (n ϭ 16) for 2 wk prior to anesthesia and lateral fluid percussion brain injury (n ϭ 31) or sham injury (n ϭ 9). Normally fed animals were then randomized to receive magnesium chloride (125 mol, i.v., n ϭ 10) or vehicle solution (n ϭ 11) at 10 min postinjury. Magnesium treatment reduced cortical cell loss (p Ͻ 0.05), cortical alterations in microtubule-associated protein-2 (MAP-2) (p Ͻ 0.05), and both cortical and hippocampal calpain-mediated spectrin breakdown (p Ͻ 0.05 for each region) when compared to vehicle treatment. Conversely, magnesium deficiency prior to brain injury led to a greater area of cortical cell loss (p Ͻ 0.05 compared to vehicle treatment). Moreover, brain injury to magnesiumdeficient rats resulted in cytoskeletal alterations within the cortex and hippocampus that were not observed in vehicle-or magnesium-treated animals. These data suggest that cortical cell death and cytoskeletal disruptions in cortical and hippocampal neurons may be sensitive to magnesium status after experimental brain injury, and may be mediated in part through modulation of calpains.
INTRODUCTION
Clinical studies have shown that central nervous system (CNS) injury results in marked alterations in blood and brain levels of magnesium (Mg) (1) (2) (3) . Animal models of CNS injury have been utilized to delineate the regional and temporal profiles of brain total and intracellular free magnesium concentrations in the injured CNS. Following concussive traumatic brain injury (TBI), brain intracellular free magnesium concentrations ([Mg 2ϩ f ] i ) markedly decrease within the first hour, and remain depressed up to 4 to 5 days postinjury (4) (5) (6) (7) (8) . Total concentrations of brain magnesium ([Mg] t ) also decrease, but to a lesser extent than observed for intracellular free magnesium (5, 9, 10) . Traumatic injury to white matter of the brain or spinal cord also results in decreased total tissue and intracellular free magnesium (7, (11) (12) (13) (14) (15) .
A critical role for magnesium in the pathobiology of TBI has been suggested by studies that show that magnesium deficiency prior to induction of experimental brain injury is associated with significantly higher mortality, worsened neurological outcome, and depressed bioenergetic status in the CNS (16) . In contrast, supplementation of magnesium prior to injury attenuates posttraumatic decreases in brain [Mg] f and improves neuromotor function and cellular bioenergetic state in rats (16) .
Moreover, the therapeutic efficacy of postinjury administration of magnesium salts has been established in animal models of TBI using a number of biochemical and neurobehavioral outcome measures. Administered following TBI in rats, magnesium has been shown to attenuate 1) regional cerebral edema, 2) decreases in brain [Mg] f , 3) decreases in blood levels of ionized Ca 2ϩ and Mg 2ϩ , 4) memory dysfunction, and 5) neuromotor deficits (15, (17) (18) (19) (20) (21) (22) (23) .
Recently, magnesium supplementation has been shown to attenuate cortical but not hippocampal CA3 cell death at 2 wk after TBI in rats (24) . The onset of cortical and hippocampal neuronal damage following experimental TBI is rapid and a substantial proportion of cell death in these regions appears to occur within the first several days after injury (25) (26) (27) (28) . A number of studies now suggest that trauma-induced neuronal cell death may be preceded by the disruption of the neuronal cytoskeleton (29) (30) (31) (32) . Consequently, the degradation or loss of microtubule-associated protein-2 (MAP-2) and the actinassociated protein spectrin serve as sensitive and reliable markers of neuronal injury (33) (34) (35) . Calcium-activated proteases (calpains) preferentially cleave many cytoskeletal proteins such as spectrin and MAP-2 and are believed to contribute to cytoskeletal damage and subsequent cell death following traumatic injury (30, 36, 37) . Both degradation of spectrin by calpains (29, 30, 38) and loss of MAP-2 protein (31, (39) (40) (41) (42) (43) are observed within minutes to hours after experimental TBI in regions which later exhibit cell death.
To determine whether the ability of magnesium to modulate outcome following brain injury may be related to its ability to influence cellular damage, we examined the effects of post-traumatic administration of magnesium chloride or pre-existing magnesium deficiency on cortical and hippocampal cell loss at 24 hours (h) after experimental TBI. We hypothesize that fluctuations in brain ionic magnesium levels in response to magnesium treatment or deficiency may, in turn, alter ionic calcium homeostasis after trauma. To investigate the potential for magnesium supplementation or deficiency to affect cell viability through calcium-sensitive pathways, we evaluated posttraumatic changes in MAP-2 and calpain-mediated proteolysis of spectrin.
MATERIALS AND METHODS

Subjects
Adult, male Sprague-Dawley rats (n ϭ 40) were housed in a Thoren vivarium on a 12-h light/dark cycle with access to food and water ad libitum. One group of rats (n ϭ 16) was placed on a magnesium-deficient diet (Dyets, Inc., Bethlehem, PA) for 14 days prior to surgery and brain injury. Preliminary studies showed that this feeding regimen results in a reduction in plasma total magnesium concentration from 1.6 mg/dl to less than 0.2 mg/dl and a decrease in plasma magnesium ion concentration of approximately 50% (unpublished observations), consistent with published data (16) . The remaining animals (n ϭ 24) received a diet of standard rat chow. At the time of surgery, magnesium-deficient rats weighed 356 Ϯ 3 g (mean Ϯ SEM) and normally fed animals weighed 382 Ϯ 2 g. All procedures described herein were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania and were performed in accordance with standards published by the National Research Council (44).
Surgery and Fluid Percussion Brain Injury
Rats (n ϭ 40) weighing 350-400 g were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and placed in a stereotaxic frame. Following the original, published protocol for lateral fluid percussion (FP) brain injury (45), a 5-mm diameter craniotomy was created over the left parieto-temporal cortex, midway between lambda and bregma, leaving the dura mater intact. The animal was then attached to the FP device via a Luer-Lok connector cemented to the skull at the craniotomy site. Animals (n ϭ 13 magnesium deficient, n ϭ 18 normally fed) were subjected to lateral FP brain injury of moderate severity (2.3-2.7 atm) by the rapid contact of a bolus of saline with the dural surface. Sham-injured (control) animals (n ϭ 3 magnesium deficient, n ϭ 6 normally fed) underwent all anesthetic and surgical procedures but did not receive FP brain injury.
Administration of Magnesium or Vehicle Solution
Following brain injury or sham procedures, the surviving normally fed animals were randomized into either magnesium chloride or vehicle treatment groups. At 10 min following injury, the right femoral vein of the anesthetized animal was exposed and a 28G1/2 needle securely attached to polyethylene tubing was inserted. Animals then received a 15 min infusion of either 0.5 ml of 250 mM magnesium chloride (125 mol; n ϭ 7 injured, n ϭ 3 sham) or an equal volume of saline vehicle solution (n ϭ 8 injured, n ϭ 3 sham) delivered by a syringe pump. The surviving magnesium deficient rats (n ϭ 8 injured, n ϭ 3 sham) received vehicle solution using identical administration parameters. Following the infusion of magnesium or vehicle, all incisions were closed with suture. Animals recovered from anesthesia while on a heating pad and were returned to their cages upon ambulation.
Sacrifice and Tissue Preparation
At 24 h following injury, animals were overanesthetized with sodium pentobarbital (200 mg/kg, i.p.) and transcardially perfused with heparinized saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Brains were removed from the cranium, placed in fixative for 3 h and then in 30% sucrose solution. Sucrose infiltrated brains were frozen in 2-methyl butanol at Ϫ40ЊC, stored at Ϫ80ЊC, and then cut into 40 m-thick coronal sections on a sliding microtome.
Histological and Immunohistochemical Staining
Previous work with the lateral FP brain injury model has shown that at 2 wk postinjury the cortical cavity spans from at least Ϫ1.3 mm to Ϫ6.3 mm Bregma, with maximal cavity area at Ϫ4.3 mm Bregma (46) . For histological and immunohistochemical evaluations at 24 h postinjury, we selected 2 regions near the maximal lesion area (Ϫ3.3 and Ϫ5.3 mm Bregma) which would also allow evaluation of rostral and caudal hippocampal structures that have been shown to exhibit disruptions of spectrin, MAP-2, and NF cytoskeletal proteins (30, 31, 39) .
For evaluation of cell damage/tissue loss, coronal sections from each animal were mounted onto gelatin-coated slides, airdried, and stained with either 5% cresyl violet or with hematoxylin and eosin (H&E). For detection of calpain-mediated spectrin proteolysis, adjacent sections were labeled with a polyclonal antibody against the COOH-terminus of the NH 2 -terminal fragment of spectrin generated specifically by calpain (1: 10,000 Ab38, rabbit IgG; gift from Dr. R. Siman, Department of Pharmacology, University of Pennsylvania) (35) . To examine alterations in MAP-2 protein, sections were labeled with an antibody specific for MAP-2 (1:400 AP20, mouse IgG; Boehringer Mannheim, Indianapolis, IN) (47, 48) . For immunohistochemical labeling, tissue sections were treated with 0.9% H 2 O 2 in 50% methanol, blocked in 5% normal horse serum, and incubated overnight in primary antibody. Tissue sections incubated overnight in serum without primary antibody served as negative controls. Tissue sections were immersed in biotinylated secondary antibody (1:1,000 dilution of goat anti-rabbit or donkey anti-mouse IgG; Jackson ImmunoResearch, West Chester, PA) followed by horseradish peroxidase-conjugated streptavidin (1:1,000, Jackson ImmunoResearch). Nickel sulfate-enhanced diaminobenzidine tetrahydrochloride solution was used to visualize the reaction product. Each histological or immunohistochemical stain was performed on all tissue sections at the same time in order to reduce inter-animal staining variability.
Analysis of Histology and Immunohistochemistry
All histological and immunohistochemical analyses were performed by trained personnel who were blinded to the treatment and injury status of the animals. Cortical lesion area for each brain-injured animal was quantified using H&E-stained sections. Under low-power light microscopy, an image of the injured cortical region was captured by video camera. The borders of the injured area were manually traced on the image using criteria of decreased pallor and/or the presence of eosinophilic neurons to define the injured region. This technique was performed on H&E-rather than cresyl violet-stained sections because of the improved sensitivity of delineating the edges of the lesion afforded by H&E staining. The area of this cortical lesion was then automatically calculated using an image analysis software routine (MCID/M4, Imaging Research, St. Catherines, Ontario). Hippocampal CA3 cell damage was expressed as a percent decrease in the total area of cells that exhibit normal intensity Nissl staining in the ipsilateral CA3 region relative to the equivalent region in the contralateral hippocampus. Using image analysis software (MCID/M4), a gray level threshold was set for each animal to detect the entire pyramidal cell layer within a segment of the contralateral (uninjured) CA3 region at Ϫ5.3 mm Bregma measuring 600 m in length by 250 m in width on average. Using this same threshold, the area of stained cells was automatically detected in an equivalent region in the ipsilateral hippocampus. We have shown previously that FP brain injury produces extensive loss of CA3 pyramidal neurons at this rostro-caudal location (25, 49) . However, hippocampal CA3 damage measured as a decrease in the area of normal intensity Nissl staining may reflect a loss of cells, a decrease in Nissl staining, or shrinkage of cells.
To determine quantitatively if magnesium supplementation or deficiency influenced calpain-mediated proteolysis of spectrin, the area of Ab38 immunoreactivity was measured in the ipsilateral cortex for brain sections taken at Ϫ3.3 and Ϫ5.3 mm Bregma. Low magnification images of immunolabeled sections were captured and the region of staining was detected automatically using the threshold function of the image analysis software. Because uninjured areas showed no staining, the area of spectrin breakdown product labeling could be selected in a highly reproducible manner. We have previously shown that calpain-mediated spectrin proteolysis in the hippocampal CA3 region begins in the stratum oriens and progresses into the pyramidal cell layer, followed by the stratum radiatum and stratum lacunosum moleculare (30) . Therefore, in a brain section taken at Ϫ5.3 mm Bregma, the extent of hippocampal spectrin proteolysis was ranked semiquantitatively according to the number of hippocampal CA3 strata involved, as described previously (50) . Specifically, a rank of 0 was given for Ab38 immunoreactivity in none of the CA3 layers; a rank of 1 for staining in the stratum oriens alone; a rank of 2 for staining in the stratum oriens and stratum pyramidale; a rank of 3 for staining in the stratum oriens, stratum pyramidale, and stratum radiatum; and a rank of 4 for staining in the stratum oriens, stratum pyramidale, stratum radiatum, and stratum lacunosum moleculare.
MAP-2 immunohistochemical staining was evaluated within the cortex and the CA3 and dentate hilar regions of the hippocampus. At Ϫ3.3 and Ϫ5.3 mm Bregma, the cortical region of altered MAP-2 labeling was identified under high power (ϫ100) and then traced on an image captured under lower magnification (ϫ40). The area of the outlined region was then calculated (MCID/M4 image analysis software). Immunoreactivity in the ipsilateral CA3 region at Ϫ5.3 mm Bregma and in the dentate hilus was semiquantitatively scored, using a method based on previously published studies of MAP-2 immunohistochemistry and CNS injury (43, 51) . The extent and severity of MAP-2 alterations were subjectively rated as 0 for no change, 1 for mild change (i.e. a partial loss of MAP-2 immunoreactivity within the CA3 region or the hilus or an overt loss of immunoreactivity restricted to a small area of the CA3 region), and 2 for moderate change (i.e. overt decrease in MAP-2 immunoreactivity within the hilus or within a moderate or large area of the CA3 region).
Statistical Analyses
The incidence of mortality was compared between normomagnesemic and hypomagnesemic animals using a Fisher's exact test. Injury levels were compared by a one-way ANOVA followed by post-hoc Newman-Keuls t-tests. Cortical lesion areas (for H&E, spectrin, and MAP-2) and rankings for hippocampal spectrin breakdown, CA3 MAP-2, and dentate hilar MAP-2 were analyzed by a Kruskal-Wallis ANOVA followed by Mann-Whitney t-tests for individual comparisons. Nissl staining of the hippocampal CA3 was evaluated by a two-way ANOVA.
RESULTS
All groups of injured animals (magnesium-treated, vehicle-treated, and magnesium-deficient) were subjected to equivalent levels of injury (2.46 Ϯ 0.05, 2.56 Ϯ 0.03, and 2.62 Ϯ 0.02 atm, respectively; mean Ϯ SEM; p Ͼ 0.05). Five of 13 magnesium-deficient animals (38%) and 3 of 18 normally fed animals (17%) died after receiving brain injury. There was no statistically significant difference in these mortality rates.
Histological Effects of Magnesium on the Cortex and Hippocampal CA3 Region
Sham-injured animals, regardless of treatment, showed no cortical lesion or hippocampal CA3 cell damage (data not shown). In contrast, all brain-injured animals exhibited a cortical lesion, evident as a decrease in intensity of H&E staining. Quantification of lesion area revealed that magnesium treatment significantly reduced the size of the cortical lesion at Ϫ3.3 mm Bregma (p Ͻ 0.05) and Ϫ5.3 mm Bregma (p Ͻ 0.05) when compared to vehicle treatment (Fig. 1A, B) . Conversely, brain injury resulted in significantly larger cortical lesions in magnesium-deficient animals at both Ϫ3.3 mm (p Ͻ 0.05) and Ϫ5.3 mm (p Ͻ 0.01) Bregma than in normally fed animals treated with vehicle (Fig. 1A, B 
Effects of Magnesium on Spectrin Proteolysis by Calpain
Sham-injured animals, regardless of treatment, and tissue sections incubated without primary antibody were devoid of calpain-mediated spectrin breakdown product immunoreactivity in all brain regions examined. In contrast, proteolysis of spectrin as a result of calpain activation occurred in the ipsilateral cortex of all brain-injured animals ( Fig. 2A-C, E-G) . The cellular staining pattern was qualitatively similar among groups and to previously published observations (30) . Within the lesion, neuronal cell bodies were darkly stained, shrunken and pyknotic, with short, immunoreactive processes, while at the periphery of the lesion, immunoreactive cells tended to exhibit more normal morphology and longer immunoreactive processes. However, at Ϫ3.3 mm Bregma, the cortical area exhibiting calpain-generated spectrin fragments was significantly smaller in brain-injured animals that received postinjury magnesium chloride compared to that in magnesium-deficient, brain-injured animals (p Ͻ 0.05; Fig. 2D ). Furthermore, postinjury magnesium-treatment resulted in a significantly smaller region of cortical calpain-mediated spectrin proteolysis at Ϫ5.3 mm Bregma than did vehicle treatment (p Ͻ 0.05) or magnesium deficiency (p Ͻ 0.005) (Fig. 2H) .
Within the ipsilateral hippocampus of brain-injured animals, calpain-mediated spectrin breakdown was consistently observed in the CA3 region at Ϫ5.3 mm Bregma. Proteolytic fragments were localized throughout all strata of the CA3 region and occasionally within a small region of CA1 in vehicle-treated and magnesium deficient animals (Fig. 2J, K) . In contrast, magnesium-treated animals exhibited markedly reduced hippocampal spectrin breakdown, typically limited to the pyramidal cells and stratum oriens of the CA3 region and never involving the CA1 region (Fig. 2I) . Semiquantitative analyses revealed a significant reduction in the number of CA3 strata exhibiting calpain-generated spectrin fragments in animals that received magnesium chloride as compared to vehicle (p Ͻ 0.05, Fig. 2L ). Within the molecular layer of the ipsilateral dentate gyrus, a diffuse punctate pattern of spectrin breakdown product immunoreactivity was commonly observed in vehicle-treated, brain-injured animals. An equivalent pattern of staining was noted in magnesiumtreated animals. Interestingly, calpain-mediated spectrin degradation was not detected in the molecular layer of the dentate gyrus in magnesium-deficient, brain-injured animals.
Effects of Magnesium Administration and Deficiency on MAP-2 Immunolabeling
Sham-injured (control) animals exhibited MAP-2 immunostaining around the periphery of cortical neuronal cell bodies and within short, thick apical dendrites (Fig.  3A) . This pattern was equivalent in all sham-injured animals, independent of treatment. In both vehicle-and magnesium-treated animals, brain injury resulted in a loss of MAP-2-positive cells in the injured cortex with the few remaining immunoreactive cells typically appearing lightly stained and pyknotic (Fig. 3B) . While magnesiumdeficient, brain-injured rats also exhibited a general loss of MAP-2 stained cells in the injured cortex, half (n ϭ 4 of 8) contained a distinct subset of intensely stained, pyknotic neurons scattered within the injured cortical region (Fig. 3C) . The area of the cortex displaying altered MAP-2 labeling (either increased or decreased) was significantly smaller for magnesium-treated animals ( 2 ) and largest in magnesium-deficient animals (3.88 Ϯ 0.54 mm 2 ), this was not statistically significant (p Ͻ 0.10).
In uninjured animals, MAP-2 staining patterns in the hippocampus were not affected by magnesium supplementation or deficiency. In both vehicle-treated and magnesium-deficient brain-injured rats, however, a marked decrease in MAP-2 labeling was observed in the dentate hilus of the ipsilateral hippocampus, while magnesiumtreated rats exhibited only mild loss of hilar MAP-2 staining. Semiquantitative scoring of MAP-2 immunoreactivity in the dentate hilus supported these observations, indicating a significant loss of MAP-2 in the vehicletreated and magnesium-deficient animals (p Ͻ 0.001 compared to sham-injured), but not in the magnesiumtreated group (Fig. 4A) . At 24 h following lateral FP brain injury, loss of MAP-2 immunoreactivity was also observed in the CA3 region of the ipsilateral hippocampus at Ϫ5.3 mm Bregma in vehicle-treated animals. In comparison, the decrease in CA3 MAP-2 immunolabeling appeared more pronounced in magnesium-deficient rats and less pronounced in magnesium-treated animals. Semiquantitative scoring of extent of MAP-2 alterations in the hippocampal CA3 revealed a significant disruption of MAP-2 staining in all 3 brain-injured groups ( Fig. 4B ; p Ͻ 0.05 for magnesium-treated, p Ͻ 0.001 for vehicletreated and magnesium-deficient). However, alterations in MAP-2 immunoreactivity in the ipsilateral CA3 region after brain injury were significantly milder in magnesium-treated rats compared with magnesium-deficient (p Ͻ 0.05). In the contralateral CA3 region at Ϫ3.3 mm Bregma, magnesium-deficient, brain-injured animals (n ϭ 5 of 8) exhibited a notable increase in MAP-2 immunoreactivity in the stratum oriens, pyramidal layer, and stratum radiatum that was not observed in vehicle-or magnesium-treated rats (Fig. 5) . Tissue sections incubated without primary antibody exhibited no immunoreactivity.
DISCUSSION
We have demonstrated in a model of TBI that magnesium administered in the acute post-traumatic period significantly attenuates cortical cell loss, reduces calpainmediated degradation of spectrin, and helps maintain neuronal cytoskeletal integrity. Conversely, magnesium deficiency exacerbates cortical cell loss and amplifies neuronal cytoskeletal disruption observed after TBI in rats. These findings provide important cellular evidence corroborating the beneficial effects of magnesium supplementation on neurobehavioral outcome, cerebral edema, bioenergetic state, and tissue cation balance after TBI (15, (17) (18) (19) (20) (21) (22) (23) 52) .
A significant reduction in cortical lesion area was observed at 24 h postinjury in rats that received magnesium chloride at 10 min after TBI. Together with our previous study demonstrating that magnesium chloride given at 1 h following TBI in rats significantly reduced cortical lesion size at 2 wk postinjury (24) , these data suggest that post-traumatic magnesium supplementation produces early cortical neuroprotection that is sustained at least 2 wk following trauma. Elevated extracellular magnesium has been shown to protect cultured cortical neurons from oxidative injury (53) . In addition, studies of focal cerebral ischemia in rats have established that systemic administration of magnesium either prior to (54) or immediately following (55) middle cerebral artery occlusion results in a significantly smaller cortical infarct volume. We have expanded on these previous studies by demonstrating that magnesium administration also attenuates cytoskeletal disruption after CNS injury. Following experimental TBI, both calpain-mediated spectrin breakdown and loss of MAP-2 are early events thought to be initiated prior to cell death (30, 31, 38, 56) . Post-traumatic magnesium treatment significantly reduced cortical spectrin degradation and MAP-2 loss, perhaps contributing to a reduction in cortical lesion.
Magnesium has been shown to be neuroprotective using hippocampal slice preparations subjected to anoxic or excitotoxic insults (57, 58) . Furthermore, administration of magnesium to rats has been shown to attenuate degeneration of hippocampal neurons caused by infusion of excitatory amino acid agonists (59) (60) (61) or global cerebral ischemia (62) . In the present study, no attenuation of the loss of Nissl-staining in the hippocampal CA3 region of brain-injured rats was observed. These data are consistent with our previous findings that magnesium chloride given to rats at 1 h after TBI did not protect hippocampal CA3 neurons at 2 wk (24) . The differential responses to magnesium exhibited by the cortex and hippocampus may reflect distinct mechanisms of cellular injury or inherent differences in the sensitivity of histological measurements in these regions. Magnesium treatment did, however, result in a reduction in spectrin breakdown by calpain in the hippocampal CA3 region and mild attenuation of CA3 and dentate hilar MAP-2 loss. It is possible, therefore, that magnesium supplementation may preserve the cytoarchitecture of a subset of vulnerable hippocampal neurons or neuronal processes.
Contrary to the cortical neuroprotection observed after magnesium administration, magnesium deficiency in brain-injured animals led to a larger cortical lesion area, suggestive of greater cell loss after TBI. Magnesium-deficient rats also showed a trend toward increased cortical spectrin breakdown and loss of MAP-2 after trauma. Depletion of extracellular magnesium has been shown to exacerbate kainate-induced increases in lactate and decreases in N-acetylaspartate in rat cerebral cortical slices (63) . Decreased extracellular magnesium has also been shown to result in greater cell death due to oxidative injury in cortical neuronal cultures (53) . Although magnesium deficiency enhanced cortical cell loss after TBI, no overt cell death or cytoskeletal disruption was observed in uninjured, magnesium-deficient animals. Together these data suggest that magnesium deficiency alone may not lead to cell death, but may produce vulnerability to subsequent insults in cortical neurons. Only in magnesium-deficient animals were intensely MAP-2-immunoreactive, pyknotic cortical neurons observed within the cortical lesion. This robust MAP-2 staining may be an indication of heightened cellular injury or superimposed ischemic insult, since magnesium deficiency can cause vasoconstriction (3, 64) and ischemic cortical neurons have been reported to exhibit increased perikaryal MAP-2 labeling (47, 65) . In contrast, magnesium deficiency did not appear to confer additional vulnerability to neurons in the ipsilateral hippocampus after brain injury. This again may indicate a relative insensitivity of hippocampal neurons (particularly those in the CA3 region) to magnesium-dependent processes. However, decreased extracellular magnesium has been shown to result in significantly increased [Ca 2ϩ f ] i in dissociated hippocampal pyramidal neurons (66) . It is possible, therefore, that magnesium deficiency accelerated the rate of cytoskeletal disruption and cell loss in the ipsilateral hippocampus, but that by 24 h following injury, when a majority of cell loss had occurred even in normally fed brain-injured rats, these differences were not detectable.
Magnesium inhibits the release of excitatory amino acids (67), competes with extracellular calcium, and inhibits calcium influx through both voltage-sensitive calcium channels and NMDA-subtype glutamate receptors (66, (68) (69) (70) . In addition, magnesium may affect intracellular calcium storage and release by acting as a noncompetitive inhibitor of the IP 3 -gated Ca 2ϩ channel (71), modulating mitochondrial calcium uptake (72) and preventing calcium-induced mitochondrial swelling (73) . Through these integrated pathways, magnesium may influence intracellular free calcium concentrations after trauma, indirectly altering calpain activation. Because cellular substrates for calpains may include cellular enzymes, membrane proteins, cytoskeletal proteins, and transcription factors, an indirect action of magnesium on calpain activity could affect multiple cellular functions (36, 37) . We have shown that magnesium supplementation after TBI in rats reduces proteolytic activity of calpain in the cortex and hippocampus, as evidenced by an attenuation of spectrin degradation. Conversely, magnesium deficiency prior to brain injury results in heightened cortical calpain proteolytic activity. Our data suggest that one of the cellular mechanisms by which magnesium influences outcome after traumatic injury is through indirect action on calpains.
In addition to calcium-and calpain-mediated pathways, magnesium influences numerous other cellular functions such as maintenance of membrane integrity, protein synthesis, and enzymatic activity (74) . In addition, magnesium may affect cytoskeletal components directly or indirectly, through effects on kinases or phosphatases. Elevated intracellular magnesium has been shown to disrupt assembly of microtubules and actin stress fibers in non-neuronal cells (75) , whereas crosslinking and mechanical properties of neurofilaments in suspension can be altered by increased magnesium concentrations (76) .
Alternatively, magnesium treatment or deficiency may have systemic effects that could influence pathological processes in the brain after traumatic injury. However, postinjury administration of magnesium chloride at a dose identical to that used in the present study has been shown to result in no alteration of body or brain temperature (19) and no change in arterial blood pH, pCO 2 or pO 2 (52) in brain-injured rats. Magnesium chloride (125 mol) administered at 30 min after lateral FP brain injury in rats resulted in only a small elevation in mean arterial blood pressure (MABP) at 2 h postinjury (17) . Relative to normally fed brain-injured animals, magnesium-deficient brain-injured rats exhibit a transiently elevated MABP at 30 s postinjury, normal MABP at 5 and10 min postinjury, and slightly decreased MABP at 15 and 30 min postinjury, which normalized by 1 h postinjury (16) . In addition, while dietary-induced magnesium deficiency results in lowered brain free magnesium levels (16) , it may also result in other metabolic changes that could contribute indirectly to the increased cellular damage observed in magnesium-deficient brain-injured animals.
An increase in MAP-2 immunolabeling, unique to magnesium-deficient animals after TBI, was noted in the contralateral hippocampal CA3 region. Although lateral FP brain injury of moderate severity has been shown to produce bilateral loss of dentate hilar MAP-2 (31) and hilar neurons (77) , no cell loss occurs in the contralateral CA3 region. The contralateral increase in MAP-2 may reflect an increased scope of injury due to the combination of magnesium deficiency and TBI. In a seizure model utilizing unilateral kainate injections to produce increased MAP-2 mRNA in the ipsilateral hippocampus, animals with the most severe seizures also showed contralateral increases in MAP-2 mRNA (78). Alternatively, increased MAP-2 labeling may indicate plastic remodeling initiated in the relatively intact contralateral CA3 region. Increases in MAP-1B, a developmentally regulated MAP associated with growth of neuronal processes, have been observed bilaterally in the hippocampus after lateral FP brain injury (79) .
In conclusion, we have shown that magnesium administration is effective in reducing cortical cell loss and cytoskeletal disruption after experimental brain injury, whereas magnesium deficiency exacerbates cortical histopathology. In the hippocampus, loss of CA3 Nissl staining was not affected by magnesium supplementation or deficiency, but treatment with magnesium partially preserved hippocampal neuronal cytoarchitecture. We have provided evidence that indirect effects of magnesium on calpains may play a role in the efficacy of magnesium in models of TBI. Together these data contribute to the growing understanding of the cellular basis for the therapeutic effects of magnesium in the setting of CNS injury.
